NASDAQ$RMTI
Rockwell Medical Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Rockwell Medical achieved profitability on an Adjusted EBITDA basis and record net sales, gross profit, and gross margin for the full year.
Rockwell Medical reported achieving profitability on an adjusted EBITDA basis in Q4 2023, alongside record net sales, gross profit, and gross margin for the full year 2023. The company has focused on improving financial health, securing multi-year agreements, expanding geographically, and improving manufacturing efficiencies.
- Achieved profitability on an adjusted EBITDA basis in Q4 2023.
- Generated the highest revenue and gross profit to-date for the company in 2023.
- Completed two acquisitions and renegotiated customer agreements.
- Expanded geographic footprint both domestically and internationally.
Headline financials
Revenue & EPS history
Rockwell Medical · Revenue · Quarterly
$22.1M
Forward guidance
Rockwell Medical projects net sales to grow in the mid-to-high single digits in 2025 and beyond. Rockwell Medical projects gross margin in 2025 to be approximately 20% and reaching above 25% in 2026 and beyond.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
-3.1%
Avg return
Earnings day
-3.3%
Avg return
5 days after
-3.0%
Avg return
30 days after
38%
24 / 63 earnings
Positive
+28.2%
Q3 2022
Best reaction
-43.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -13.0% | -11.3% | — | |
| Q1 2026 | -3.6% | +2.8% | -18.2% | |
| Q3 2025 | -9.2% | -17.1% | -12.4% | |
| Q1 2025 | -6.4% | -9.8% | -11.6% | |
| Q4 2024 | -20.5% | -31.8% | -41.5% | |
| Q3 2024 | -43.4% | -49.2% | -55.5% | |
| Q2 2024 | +22.6% | +35.6% | +68.4% | |
| Q1 2024 | +0.6% | +4.1% | +8.2% | |
| Q4 2023 | +3.6% | +0.0% | -12.1% | |
| Q3 2023 | +12.2% | +5.1% | -11.2% | |
| Q2 2023 | -7.4% | -25.8% | -28.5% | |
| Q1 2023 | -4.5% | -3.7% | +71.8% | |
| Q4 2022 | +14.6% | +18.4% | +74.7% | |
| Q3 2022 | +28.2% | +19.4% | +0.0% | |
| Q2 2022 | +12.0% | +7.1% | -14.1% | |
| Q1 2022 | +3.0% | -17.3% | -34.7% | |
| Q4 2021 | -13.6% | -11.4% | -27.3% | |
| Q3 2021 | -7.7% | -7.7% | -21.2% | |
| Q2 2021 | -6.2% | -10.8% | -4.6% | |
| Q1 2021 | -2.2% | -4.3% | +0.0% | |
| Q4 2020 | +4.5% | -1.8% | -13.5% | |
| Q3 2020 | +1.1% | +5.6% | +33.7% | |
| Q2 2020 | +4.2% | +0.0% | -26.3% | |
| Q1 2020 | -4.7% | -12.9% | -9.0% | |
| Q4 2019 | -42.7% | -25.0% | -22.6% | |
| Q3 2019 | +5.4% | +12.4% | +23.7% | |
| Q2 2019 | -5.6% | +2.0% | +9.3% | |
| Q1 2019 | -7.5% | -11.9% | -25.6% | |
| Q4 2018 | +3.0% | +23.9% | +4.7% | |
| Q3 2018 | +8.9% | +12.3% | -16.2% | |
| Q2 2018 | -15.5% | -12.4% | -13.6% | |
| Q1 2018 | -2.5% | +5.8% | -8.8% | |
| Q4 2017 | -17.5% | -18.3% | -14.1% | |
| Q3 2017 | +9.6% | +11.6% | +3.4% | |
| Q2 2017 | -4.2% | -1.5% | -5.4% | |
| Q1 2017 | -1.2% | -9.1% | +9.3% | |
| Q4 2016 | +10.0% | +10.2% | +10.6% | |
| Q3 2016 | -20.5% | -3.5% | +27.3% | |
| Q2 2016 | -8.9% | -8.1% | -10.2% | |
| Q1 2016 | +19.7% | — | — | |
| Q4 2015 | -36.8% | — | — | |
| Q3 2015 | -10.5% | — | — | |
| Q2 2015 | +11.5% | — | — | |
| Q1 2015 | +12.9% | — | — | |
| Q4 2014 | -6.6% | — | — | |
| Q3 2014 | +5.7% | — | — | |
| Q2 2014 | +0.1% | — | — | |
| Q1 2014 | -8.5% | — | — | |
| Q3 2013 | -0.8% | — | — | |
| Q2 2013 | +0.6% | — | — | |
| Q1 2013 | -7.6% | — | — | |
| Q4 2012 | -19.9% | — | — | |
| Q3 2012 | -3.3% | — | — | |
| Q2 2012 | -6.4% | — | — | |
| Q1 2011 | -0.2% | — | — | |
| Q1 2012 | +1.0% | — | — | |
| Q4 2011 | -4.4% | — | — | |
| Q3 2011 | -9.3% | — | — | |
| Q3 2010 | -9.3% | — | — | |
| Q2 2011 | -0.1% | — | — | |
| Q2 2010 | -0.1% | — | — | |
| Q4 2010 | -1.4% | — | — | |
| Q1 2010 | +3.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro